All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Melflufen for triple-class refractory multiple myeloma | Final topline results from the phase II HORIZON study released
Bookmark this article
The final topline results from the phase II HORIZON (NCT02963493) study have recently been released. The trial investigated the efficacy and safety of melphalan flufenamide (melflufen) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).1 The results demonstrate favorable efficacy and safety profiles for melflufen in patients with RRMM, including those with triple-class refractory- and extramedullary disease (Table 1).The data from this study are set to form the foundations of a new drug application (NDA) for accelerated approval to the U.S. Food & Drug Administration (FDA).1
Table 1. Primary endpoint results of the HORIZON study
|
EMD, extramedullary disease; IRC, independent review committee; ITT, intention to treat; ORR, overall response rate *Two unconfirmed responders on January 14 have later been confirmed. |
|||
|
Primary endpoint, % |
Investigator assessed (January 14) |
IRC (January 14) |
Including unconfirmed responses at time of data cut-off * |
|---|---|---|---|
|
ORR in the ITT population (n = 157) |
29 |
30 |
31 (investigator and IRC) |
|
ORR in triple-class refractory patients (n = 119) |
26 |
26 |
27 |
|
ORR in patients with EMD (n = 55) |
24 |
27 |
NA |
A previous analysis of the HORIZON study was presented by Paul Richardson at the 24th Congress of the European Hematology Association (EHA). Read the MM Hub coverage here.
Expert Opinion
AB O. Oncopeptides Announces 26% overall response rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study. PRNewswire. https://www.prnewswire.com/news-releases/oncopeptides-announces-26-overall-response-rate-of-melflufen-in-triple-class-refractory-multiple-myeloma-patients-from-the-pivotal-horizon-study-301030250.html. Published Mar 26, 2020. Accessed Apr 27, 2020.
More about...
Your opinion matters
2 votes - 41 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox